BD partnership with Cell & Gene Therapy Catapult and the PAT consortium

Synopsis

Flow cytometry is a powerful tool to characterize cell phenotypes to define critical quality attributes for cell and gene therapy products such as cell viability, identity, potency and purity. Flow cytometry assays are performed at different stages during the development and manufacturing of cell therapy products. Assays are often transferred between multiple manufacturing sites for the final release and QC of therapeutic products.

BD was delighted to be part of the PAT Consortium group and sees the partnership as a chance to work with cell therapy developers, ultimately helping make cell therapy products more affordable, accessible and commercialised quickly.

Discover more on:

• Leading expertise in advanced multiparametric flow cytometry which is used to:
  • Assess and monitor product characterisation
  • Establish a target product profile (TPP) to define product identity, safety and potency
• BD FACSLyric™ Flow Cytometer integrated with the BD FACSDuet™ Sample Preparation System provided an efficient, automated and standardised solution
  • 20% reduction in total processing time
  • 99% reduction in error-prone steps
  • 75% reduction in hands-on time
  • Reduced staff training time
• Broad array of flow cytometry reagents including BD Horizon Brilliant™ Dyes, and BD Horizon RealYellow™ and BD Horizon RealBlue™ Fluorochromes with more than 9,000 human immunology research reagents can support cell therapy research